IP Library Granted Patent US 7,785,610
Granted Patent B2
US 7,785,610 · App. 10/328,578 · Granted Aug 31, 2010

Chimeric immunomodulatory compounds and methods of using the same—III

Assignee: Dynavax Technologies Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,610
App. No.
10/328,578
Granted
Aug 31, 2010
Kind
B2
Abstract

The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

Claims (7)

1. A method of modulating an immune response in an individual comprising administering to an individual a branched chimeric immunomodulatory compound (CIC) in an amount sufficient to modulate an immune response in said individual, wherein: the CIC comprises at least three nucleic acid moieties and one or more non-nucleic acid, spacer moieties; each nucleic acid moiety is covalently joined to at least one non-nucleic acid spacer moiety; at least one nucleic acid moiety comprises the sequence 5′-CG-3′; and said CIC has immunomodulatory activity.

2. The method of modulating an immune response of claim 1 wherein the CIC has a fork structure, an H structure, a comb structure, or a central spacer structure.

3. A method of modulating an immune response of a population of cells, comprising contacting the population with a composition comprising a branched chimeric immunomodulatory compound (CIC) wherein: the CIC comprises at least three nucleic acid moieties and one or more non-nucleic acid spacer moieties; each nucleic acid moiety is covalently joined to at least one non-nucleic acid spacer moiety; at least one nucleic acid moiety comprises the sequence 5′-CG-3′; and said CIC has immunomodulatory activity.

4. The method of modulating an immune response of claim 3 , wherein the CIC has a fork structure, an H structure, a comb structure, or a central spacer structure.

5. A method of claim 1 wherein the immunomodulatory activity is an increase in interferon-α.

6. A method of claim 1 wherein at least one of the nucleic acid moieties comprises the sequence TCG in the 5′ position.

7. A method of claim 1 , wherein two or more of the nucleic acid moieties comprises the sequence TCG in the 5′ position.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 14, 2021
From: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 056252/0515 →
SECURITY INTEREST Recorded Feb 22, 2018
From: DYNAVAX TECHNOLOGIES CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 045441/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2003
From: FEARON, KAREN L.; DINA, DINO; TUCK, STEPHEN F.
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 014071/0622 →
Continuity (5)
Continuation In Part 1017688300 · Jun 21, 2002
Continuation In Part 1017782600 · Jun 21, 2002
Provisional Application 6029988300 · Jun 21, 2001
Provisional Application 6037525300 · Apr 23, 2002
Related Publication 20030225016A1 · Dec 4, 2003